Analytical Validation of a Plasma-Based Rapid Liquid Biopsy Assay Using Next-Generation Sequencing.
A new blood-based cancer test delivers results in two days instead of weeks, potentially accelerating treatment decisions for cancer patients.
A 2-day TAT plasma cfTNA NGS assay (Oncomine Precision Assay on Genexus Sequencer) achieved >99% analytical sensitivity and specificity for SNVs/indels in 107 clinical samples, with 72.2% sensitivity for fusions; average TAT ≤2 days enabling faster treatment decisions. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- analytical validation study (n=107 clinical plasma samples, MD Anderson Cancer Center)
- Category
- early_cancer_detection
- Maturity
- Validated
- Journal
- J Mol Diagn
Why it surfaced
Institutional validation from a leading cancer center of a rapid-turnaround cfTNA NGS platform addresses a critical clinical bottleneck: most liquid biopsy assays take 5-10 days, delaying treatment initiation. A validated 2-day TAT with high analytical performance is immediately actionable.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.